The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 10, Issue 4, 2008, Pages 293-300

  Garcia Soria, Gustavo ^a   Gonzalez Galvez, G ^b   Argoud, G M ^c   Gerstman, M ^d   Littlejohn III, T W ^e   Schwartz, S L ^f   O'Farrell, A M ^g   Li, X ^g   Cherrington, J M ^g   Bennett, C ^g   Guler, Hans Peter ^g  

^a IMIC Research   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c International Clinical Research Network Inc   (United States)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e Piedmont Medical Group   (United States)

^f Diabet/Glandular Dis Res Assoc   (United States)

^g Phenomix Corporation   (United States)

Author keywords

Diabetes mellitus treatment; DPP4 inhibition; GLP 1; PHX1149T

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PHX 1149; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MEXICO; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UNITED STATES; URINARY TRACT INFECTION; VITAL SIGN; WEIGHT REDUCTION;

EID: 40749110245     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00868.x     Document Type: Article

References (18)

1. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model assessed 7-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
2. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206.
3. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
4. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343.
5. Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: Influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713.
6. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007; 298: 194-206.
7. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60: 1454-1470.
8. Ahrén B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care 2007; 30: 1344-1350.
9. Lee Y-S, Shin S, Shigihara T, Hahm E et al. Glucagonlike peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007; 56: 1671-1679.
10. O'Farrell AM, van Vliet A, Abou Farha K et al. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: Double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. Clin Ther 2007; 29: 1692-1704.
11. Bergman AJ, Stevens C, Zhou YY et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
12. Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
13. He YL, Wang Y, Bullock JM et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharm 2007; 47: 633-641.
14. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
15. Stein PP, Williams-Herman D, Khatami H et al. Sitagliptin, a selective DPP-4 inhibitor, is well tolerated in patients with type 2 diabetes: pooled analysis of 5141 patients in clinical trials for up to 2 years [Abstract]. Diabetes 2007; 56 (Suppl. 1): A142.
16. Grouzmann E, Monod M, Landis B et al. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J 2002; 16: 1132-1134.
17. Hanf G, Schierhorn K, Brunnee T, Noga O, Verges D, Kunkel G. Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis. Inflamm Res 2000; 49: 520-523.
18. JANUVIA™ (sitagliptin): Full prescribing information. Merck & Co, Inc., Whitehouse Station, NJ 2007.